Plants are nature’s oldest pharmacies. Aspirin came from willow bark. Morphine came from poppies. Quinine, the original antimalarial, came from the bark of South American Cinchona trees. Vincristine and vinblastine, two of the most widely used chemotherapy drugs, come from the Madagascar periwinkle. These aren’t accidents of folk medicine; they are real drugs, derived from real plant chemistry, that have saved millions of lives.
Now, researchers from the University of Florida and the University of British Columbia have taken an important step toward unlocking another chapter of plant-derived medicine. They sequenced and assembled the complete chromosome-level genome of Mitragyna parvifolia, a tree native to the Indian subcontinent, and used that genome to crack open one of plant biochemistry’s more intriguing mysteries: exactly how does this tree make a rare compound called mitraphylline, which has shown striking activity against breast cancer, leukemia, and sarcoma cells?
The findings were published in The Plant Cell.
What Is Mitragyna parvifolia and Why Does It Matter?
Mitragyna parvifolia belongs to the same genus as Mitragyna speciosa, the tree whose leaves are colloquially known as kratom and have attracted significant research and regulatory attention for their psychoactive alkaloids. But M. parvifolia tells a very different chemical story.
While kratom is dominated by mitragynine, a compound with opioid-like activity, M. parvifolia makes almost none of that. Instead, its young leaves are rich in a structurally distinct class of compounds called spirooxindole alkaloids, particularly mitraphylline and its isomer, isomitraphylline.
Spirooxindoles are fascinating from a medicinal chemistry standpoint. Their name describes a distinctive molecular architecture — a “spiro” junction in which two ring systems share a single carbon atom, creating a three-dimensional shape that fits unusually well into protein-binding pockets. Over 100 spirooxindole alkaloids have been identified from various plant genera, and the structural class has attracted significant pharmaceutical interest as a scaffold for drug development.
Mitraphylline itself has demonstrated antiproliferative activity, meaning it slows or stops cancer cell division, and has been shown in laboratory studies to induce programmed cell death (apoptosis) in human breast cancer, sarcoma, and leukemia cell lines. It has also been investigated for potential anti-Alzheimer’s and anti-amyloid effects. Despite this pharmacological promise, the compound has been difficult to study and exploit because nobody knew how the plant actually made it. Identifying the biosynthetic enzymes opens the door to producing it more efficiently, modifying its structure, and understanding its limits.
Building the Genome: A Map of 22 Chromosomes
To understand the chemistry of M. parvifolia, researchers first needed to read its genetic blueprint. This is a technically demanding task for a plant with a large, complex genome. M. parvifolia is likely an allotetraploid, meaning it carries four sets of chromosomes rather than the usual two, the result of an ancient hybridization event between two related species.
The team used a combination of three sequencing technologies: long-read sequencing from Oxford Nanopore (which generates long continuous stretches of DNA sequence), short-read sequencing from Illumina (which provides high accuracy), and Hi-C chromosome conformation capture (which captures how DNA physically folds inside the cell nucleus, allowing researchers to order and orient sequence fragments into complete chromosomes). The result was a chromosome-scale genome assembly comprising 22 pseudochromosomes, covering 774 million base pairs of DNA with 92.6% of the assembly placed into chromosomal structures.
Completeness was validated using a standard benchmark: 98.9% of expected single-copy genes were present in the final assembly, confirming that it is one of the highest-quality plant genome assemblies published to date.
With this reference genome in hand, the team identified 50,187 gene models encoding protein-coding instructions. It used RNA sequencing across five tissue types (young leaves, mature leaves, roots, stems, and stipules) to understand which genes are switched on where and when.
An Ancient Genome Doubling That Changed Plant Chemistry
One of the most significant genomic findings didn’t directly concern mitraphylline. It concerned evolutionary history.
By comparing M. parvifolia with 12 other plant species, including close relatives like M. speciosa and Uncaria rhynchophylla, the caffeine-producing Coffea eugenioides, and more distant relatives like the Madagascar periwinkle, the researchers identified evidence of a whole-genome duplication (WGD) event shared by the Naucleeae tribe (which includes Mitragyna and Uncaria) and Cinchona (the quinine tree), but absent from coffee.
Whole-genome duplications are evolutionary inflection points. When a plant suddenly has two copies of every gene, one copy can maintain its original function. At the same time, the other is free to accumulate mutations and take on new roles, a process called neofunctionalization. Over evolutionary time, these duplicate genes can generate entirely new biochemical capabilities, including the ability to make novel specialized metabolites.
The study found that this shared polyploidization event, which occurred roughly 30 to 38 million years ago, appears to have been a key driver in the diversification of the alkaloid chemistry that distinguishes the Cinchonoideae subfamily. Cinchona went on to produce quinoline alkaloids like quinine; Mitragyna and Uncaria went on to produce the corynanthe-type and spirooxindole alkaloid: different chemistry, but both arising from the same genetic founding event.
Tracing the Assembly Line: Three Enzymes, One Unusual Compound
The paper’s central discovery is the elucidation of the complete biosynthetic pathway for mitraphylline. This is the part where plant biochemistry becomes genuinely elegant.
All monoterpene indole alkaloids (MIAs), the large chemical family that includes mitraphylline, vincristine, quinine, and mitragynine, share a common starting point: the condensation of two compounds, tryptamine and secologanin, catalyzed by an enzyme called strictosidine synthase. This produces strictosidine, the universal precursor for over 3,000 MIA structures found across multiple plant families. From strictosidine, different plants diverge into distinct enzymatic pathways to produce their characteristic alkaloids.
In M. parvifolia, strictosidine is converted through a series of well-understood steps to ajmalicine, a compound that is already known to accumulate in the plant. The team’s task was to figure out what happens next, how ajmalicine gets transformed into the unusual spirooxindole architecture of mitraphylline.
Using a combination of gene expression data (looking for genes highly expressed in the young leaves where mitraphylline accumulates most), correlation analyses (identifying genes whose expression patterns track closely with the known pathway enzymes), and functional testing in Nicotiana benthamiana (tobacco leaves used as a test platform for plant enzymes), they identified and validated three key enzymes:
MpAO (ajmalicine oxidase): A FAD-dependent enzyme that oxidizes ajmalicine at a specific bond, creating an unstable intermediate (dehydroajmalicine). FAD-dependent enzymes use a cofactor called flavin adenine dinucleotide to catalyze oxidation reactions — they’re common workhorses in secondary metabolism.
MpDAR (dehydroajmalicine reductase): An isoflavone reductase-type enzyme that reduces the intermediate produced by MpAO, but does so with a specific geometric outcome; it flips the stereochemistry at a key carbon atom, converting (3S)-ajmalicine to its mirror-image isomer (3R)-epi-ajmalicine. This stereochemical inversion is essential because the next enzyme in the pathway will only accept the (3R) form.
MpSOS (spirooxindole synthase): A cytochrome P450 enzyme, the class of enzymes responsible for many of the most complex chemical transformations in plant metabolism, that takes (3R)-epi-ajmalicine and converts it into mitraphylline and isomitraphylline through an oxidative rearrangement that creates the distinctive spirocyclic oxindole scaffold.
The researchers demonstrated that all three enzymes are required; removing any one of them from the cascade eliminates mitraphylline production. The sequence was confirmed using authentic chemical standards, and the products matched precisely. MpSOS also proved to be versatile: it could accept other related substrates and generate a range of additional spirooxindole compounds, suggesting it is a key enzyme in the broader diversification of spirooxindole chemistry in Rubiaceae plants.
Importantly, MpAO and MpDAR appear to be unique to M. parvifolia among the species studied; they are not found in closely related M. speciosa. This helps explain why the two species, despite sharing most of their biochemical machinery, end up with such dramatically different alkaloid profiles.
Why This Matters: From Plant to Medicine
Understanding the biosynthetic pathway for mitraphylline has several practical implications.
First, it makes metabolic engineering feasible. Now that the enzymes are identified and characterized, researchers can, in principle, introduce them into fast-growing microorganisms or plant hosts and produce mitraphylline in fermentation tanks rather than harvesting it from trees. This is how many modern pharmaceutical compounds are produced. The same logic produced semi-synthetic artemisinin for malaria treatment and enabled the engineering of yeast strains that produce the opioid precursor thebaine.
Second, the enzyme structures and substrate tolerances revealed by MpSOS suggest opportunities for generating structural variants of mitraphylline that may have improved potency, selectivity, or pharmacokinetic properties as drug candidates. MpSOS can accept multiple related substrates, which means the enzyme may serve as a platform for combinatorial biosynthesis.
Third, the comparative genomics findings, particularly the identification of the whole-genome duplication and the expansion of key enzyme families, provide a framework for understanding why different members of the Rubiaceae family produce such chemically diverse alkaloids. This could guide the discovery of novel bioactive compounds from related plants that haven’t yet been studied.
The Bigger Picture
The M. parvifolia genome is part of a growing wave of plant genome projects focused on species with pharmaceutical relevance. The same family, Rubiaceae, gave us quinine, ipecac, and coffee. The same biosynthetic machinery, modified and extended by millions of years of evolutionary tinkering, gave rise to more than 3,000 distinct alkaloid structures across multiple plant families, several of which are now essential medicines.
Each time researchers decode a new plant genome and trace its specialized chemistry to the enzymes that produce it, they add another reference point to a map of biological possibility. The pathway to mitraphylline, running through three specific enzymes in the young leaves of an Indian tree, is now part of that map, and it brings one more plant compound within reach of the tools of modern medicine.
Reference
Laforest, L. C., Nguyen, T.-A. M., Matsumoto, G. O., Ramachandria, P., Chanderbali, A., Kanumuri, S. R. R., Sharma, A., McCurdy, C. R., Dang, T.-T. T., & Nadakuduti, S. S. (2025). A chromosome-level Mitragyna parvifolia genome unveils spirooxindole alkaloid diversification and mitraphylline biosynthesis. The Plant Cell, 37, koaf207. https://doi.org/10.1093/plcell/koaf207